Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
To observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related…
- Trial name
- EVOLVE (NCT05060315)
- Testing
- Remunity Pump for Remodulin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
This study will evaluate the safety, tolerability and efficacy of open-label fluoxetine for three months among patients with pulmonary arterial hypertension.
- Trial name
- NCT00942708
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Texas Southwestern Medical Center
Pulmonary Arterial Hypertension
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin.
- Trial name
- NCT06554301
- Testing
- empagliflozin in treatment pulmonary aerterial hypertension
- Where
- China
- Volunteers
- 72 people
- Sponsor
- China National Center for Cardiovascular Diseases
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after…
- Trial name
- CAPACITY (NCT04084678)
- Testing
- Ralinepag
- Where
- 33 sites in United States, Argentina and 10 more
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
The purpose of this study is to evaluate how safe Opsynvi (macitentan/tadalafil fixed-dose combination) is in adult participants with pulmonary arterial hypertension under routine clinical practice in Korea.
- Trial name
- Opsynvi RMP (NCT07890285)
- Volunteers
- 333 people
- Sponsor
- Janssen Korea, Ltd., Korea
Pulmonary Arterial Hypertension
OPsumit USers Registry
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with…
- Trial name
- OPUS (NCT02126943)
- Testing
- Opsumit (macitentan)
- Where
- 146 sites in United States, Puerto Rico
- Volunteers
- 2,686 people
- Sponsor
- Actelion
Pulmonary Hypertension
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models.
- Trial name
- NCT02587325
- Testing
- nab-sirolimus
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on pulmonary artery pressure and right heart…
- Trial name
- NCT03637140
- Testing
- Simulated Altitude (FiO2: 15.1%)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension, Healthy
Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand [11C]PBR28) in the lungs of patients living with PAH relative to age matched controls.
- Trial name
- NCT05745961
- Testing
- TSPO PET scan (11C-PBR28)
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Pulmonary Hypertension
PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature leading to elevated pulmonary pressure and right ventricular (RV) dysfunction with heart failure.
- Trial name
- PAHTCH (NCT01586156)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Pulmonary Hypertension Associated With Connective Tissue Disease
VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension
Sildenafil is a selective pulmonary vasodilator; in patients with a special kind of pulmonary hypertension it is approved for treatment.
- Trial name
- SIL-REACT (NCT01889966)
- Testing
- Sildenafil
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Kerckhoff Heart Center
Pulmonary Arterial Hypertension
Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost
Patients with pulmonary arterial hypertension (PAH) suffer from breathlessness, poor quality of life and inability to function, despite medical therapy Current consensus states that combination therapy with different classes of…
- Trial name
- NCT01649739
- Testing
- Levitra
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Pulmonary Arterial Hypertension
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years.
- Trial name
- MOVE PAH) (NCT05464095)
- Testing
- mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other…
- Trial name
- NCT05224531
- Testing
- CS1 Administration
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Cereno Scientific AB
Pulmonary Arterial Hypertension
Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development…
- Trial name
- NCT05135000
- Testing
- LTP001
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Contrast Enhanced PA Pressure Measurements
Pulmonary hypertension (PH) is an abnormal increase of the pressure inside the lung circulation. This condition can be caused by many different diseases.
- Trial name
- NCT06240871
- Testing
- Pulmonary artery pressure measurements
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Northwestern University
Pulmonary Arterial Hypertension
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment.
- Trial name
- VIP (NCT03556020)
- Testing
- Pemziviptadil (PB1046)
- Where
- 26 sites in United States
- Volunteers
- 35 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Subcutaneous Elafin in Healthy Subjects
A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult subjects.
- Trial name
- NCT03522935
- Testing
- Elafin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roham T. Zamanian
Pulmonary Arterial Hypertension
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH).
- Trial name
- PHoenix (NCT05825417)
- Testing
- Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Eisenmenger Complex
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome
In this study, the investigator will evaluate the treatment effects and safety, patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan.
- Trial name
- NCT04732650
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center